Form 8-K - Current report:
SEC Accession No. 0001193125-20-168359
Filing Date
2020-06-15
Accepted
2020-06-15 07:36:40
Documents
14
Period of Report
2020-06-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d944403d8k.htm   iXBRL 8-K 29167
2 EX-99.1 d944403dex991.htm EX-99.1 8518
6 GRAPHIC g944403image1.jpg GRAPHIC 10410
  Complete submission text file 0001193125-20-168359.txt   183140

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgen-20200611.xsd EX-101.SCH 3081
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgen-20200611_lab.xml EX-101.LAB 18907
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgen-20200611_pre.xml EX-101.PRE 11870
9 EXTRACTED XBRL INSTANCE DOCUMENT d944403d8k_htm.xml XML 3513
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-14656 | Film No.: 20961917
SIC: 2836 Biological Products, (No Diagnostic Substances)